IMU Biosciences
- Company typePrivate
- Founded2021
- HeadquartersLondon, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingServices
IMU Biosciences firmographics
Firmographics- Name
- IMU Biosciences
- Legal name
- MELIO HEALTHCARE LTD.
- Website
- https://imubiosciences.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
IMU Biosciences industry classification
Industry- Product category
- Immune Profiling Platform / Precision Medicine
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF)
Keywords
Where IMU Biosciences is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
IMU Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Biopharmaceutical Partnership Services: IMU works with pharma, biotech and diagnostics companies to turn immune insight into clinical action. Services include discovery of novel immune signatures, patient stratification, biomarker identification, and translational research support across drug development.
- Clinical Programme Development: Developing proprietary clinical programmes including HSCT predictive screening tools, SOT rejection prediction tools, and I-O response biomarkers for pharmaceutical partnerships.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
IMU Biosciences product offering
Product offeringCore offering
IMU Biosciences develops and operates a proprietary HD Immunology (High Definition Immunology) platform that combines high-parameter spectral cytometry with real-time AI analytics to generate systems-level immune profiles from a single 2ml blood sample. The platform measures over 100 million data points and resolves 2,500 discrete immune cell subsets, and is offered to pharmaceutical, biotech, diagnostics companies and clinical research groups through strategic partnerships to support drug discovery, patient stratification, biomarker identification, and translational research.
Product overview
IMU Biosciences offers HD Immunology, a unified platform combining three integrated layers: (1) High-Definition Multi-Omic Immune Profiling using spectral cytometry technology to resolve 2,500 immune cell subsets from a single blood sample; (2) Proprietary Real-Time AI Analytics engine that processes 100M+ data points and generates predictive models; and (3) an expanding Immune Database of 25,000+ samples building toward the world's largest population-level immune dataset. The platform powers three clinical development programmes in HSCT (Hematopoietic Stem Cell Transplantation), SOT (Solid Organ Transplantation), and I-O (Immuno-Oncology), and supports the MANIFEST research consortium for cancer immunotherapy biomarkers.
Differentiator
Problem solved
Functional benefit
Products and services
- HD Immunology Platform IMU's core proprietary platform combining massively high-parameter spectral profiling with real-time AI analytics to generate systems-level immune profiles, measuring over 100 million data points from a single 2ml blood sample and resolving 2,500 discrete immune cell subsets. Offered to pharmaceutical, biotech, diagnostics, and clinical research customers through strategic partnerships.
- CytAtlas Platform Branded AI-powered immune profiling technology platform that translates vast system-level immune data into actionable insights for precision medicine development in immuno-oncology, cell therapy, and transplantation.
- HSCT Programme (Hematopoietic Stem Cell Transplantation) First-in-class predictive screening tool for graft efficacy in Hematopoietic Stem Cell Transplantation, targeting patient outcomes in both relapse and Graft vs Host Disease (GvHD), in clinical development phase.
- SOT Programme (Solid Organ Transplantation) Predictive signatures of early transplant rejection, differential aetiologies of rejection, and graft infection for solid organ transplantation, in discovery/validation phase.
- I-O Programme (Immuno-Oncology) Systems-level immune signatures of cancer across the patient journey from early detection to treatment and monitoring, including prediction of response to immune checkpoint inhibitors and immune-related adverse events, in validation phase.
Quantifiable outcome
- 100 million+ data points measured from 2ml of blood
- +3 more outcomes
Companies that use IMU Biosciences
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
IMU Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability4 records
Feature5 records
IMU Biosciences partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core, flagship and supporting.
- Waters CorporationcoreStrategic partnership to develop IMU's AI-powered High Definition Immunology platform combining Waters' flow cytometry and single-cell technologies (BD FACSDiscover, BD Rhapsody Instruments) with IMU's AI analytics. The platform analyzes over 100 million data points from a single blood sample. Partnership supports IMU's goal of building the world's largest immune dataset and establishing a universal standard for immune profiling.
- MANIFEST Consortium (Francis Crick Institute and Royal Marsden NHS Foundation Trust)flagshipIMU participates in MANIFEST (Multiomic Analysis of Immunotherapy Features Evidencing Success and Toxicity), a £21.9M UK-wide platform (£9M from MRC/Office for Life Sciences plus £12.9M industry match) investigating patient response to cancer immunotherapies. IMU will analyze thousands of blood samples using its platform across 6,000 patients in melanoma, renal cell carcinoma, bladder cancer, and triple-negative breast cancer studies.
- NVIDIA Inception ProgrammesupportingIMU joined NVIDIA Inception Programme to accelerate AI-driven precision medicine. The programme supports startups with tools, expertise and go-to-market resources for AI development.
Scale indicators6 records
Recent moves8 records
Expansion highlights6 records
IMU Biosciences competitors and assessment
Company assessmentBroad incumbents
- Becton Dickinson (BD Biosciences): Global leader in flow cytometry (BD FACSDiscover, BD Rhapsody) — the very instruments IMU integrates with via Waters. Comparable as the upstream platform provider whose installed base IMU is layering AI analytics on top of.
- NanoString Technologies (now part of Bruker): Spatial biology and multi-omic profiling platform (GeoMx, CosMx) used in translational immunology and immuno-oncology research. Competes with IMU for pharma and academic translational research budgets in immune biomarker discovery.
- Olink Holding: Proteomics platform (PEA technology) widely adopted in pharma biomarker discovery and translational research. Overlaps with IMU's immune-profiling and biomarker-discovery value proposition, particularly for high-plex protein measurement from small samples.
- 10x Genomics: Established provider of single-cell multi-omics platforms (Chromium, Visium) that overlap with IMU's high-throughput single-cell proteomics/transcriptomics layer. A much larger incumbent competing for similar pharma R&D and translational research budgets.
- Eurofins Scientific: Large global CRO and specialty diagnostics provider offering biomarker, immune and cell-based assay services to pharma. Comparable to IMU's services layer as a partner of choice for pharma translational and clinical trial laboratory work.
Emerging players
- Cellarity: AI-driven single-cell biology company using multi-omic data and ML to discover therapeutics. Adjacent to IMU in applying AI to high-dimensional immune/cellular data for pharma R&D, though focused on drug discovery rather than biomarker services.
Direct peers
- Cytobank (Beckman Coulter Life Sciences): Cloud platform for high-dimensional cytometry data analysis with AI/ML capabilities, used by immunology researchers and pharma. Closely comparable to IMU's analytical software layer (CytAtlas) for translating spectral cytometry data into biological insight.
- Standard BioTools (formerly Fluidigm): Provider of high-parameter cytometry and mass cytometry instruments (Hyperion, CyTOF) used in deep immune profiling. Directly comparable to IMU in enabling high-dimensional immune phenotyping, and notably connected through IMU's NED Carlos Paya, formerly Chairman.
- Adaptive Biotechnologies: Immune profiling company leveraging high-throughput TCR/BCR sequencing and ML to develop immune-based diagnostics and drug-discovery biomarkers. Comparable to IMU in combining immune-system data at scale with AI to serve pharma diagnostics and development.
- Immunai: AI-driven immune profiling company combining single-cell genomics with proprietary ML models to map the immune system. The closest direct competitor to IMU in building an AI-native immune mapping platform for pharma drug discovery and clinical translation.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
IMU Biosciences social profiles
Digital presenceIMU Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
IMU Biosciences leadership team
Management profileNumber of profiles
Profiles7 records
IMU Biosciences funding detail
Funding detailFunding overview
Funding rounds4 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
IMU Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about IMU Biosciences
What does IMU Biosciences do?
IMU Biosciences develops and operates a proprietary HD Immunology (High Definition Immunology) platform that combines high-parameter spectral cytometry with real-time AI analytics to generate systems-level immune profiles from a single 2ml blood sample. The platform measures over 100 million data points and resolves 2,500 discrete immune cell subsets, and is offered to pharmaceutical, biotech, diagnostics companies and clinical research groups through strategic partnerships to support drug discovery, patient stratification, biomarker identification, and translational research.
Is IMU Biosciences a public or private company?
IMU Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was IMU Biosciences founded?
IMU Biosciences was founded in 2021. It employs 51 to 100 people.
Where is IMU Biosciences based?
IMU Biosciences is headquartered in London, United Kingdom, in the Europe region.
How does IMU Biosciences make money?
Two revenue lines are on record. Biopharmaceutical Partnership Services are the primary driver. The others are clinical Programme Development.
Who are IMU Biosciences's main competitors?
Broad incumbents on record are Becton Dickinson (BD Biosciences), NanoString Technologies (now part of Bruker), Olink Holding, 10x Genomics and Eurofins Scientific. Cellarity is listed as an emerging player. Direct peers are Cytobank (Beckman Coulter Life Sciences), Standard BioTools (formerly Fluidigm), Adaptive Biotechnologies and Immunai.
Does IMU Biosciences have an API?
No public API is recorded for IMU Biosciences.
What industry is IMU Biosciences in?
IMU Biosciences's product category is Immune Profiling Platform / Precision Medicine. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry). Its NAICS code is 621511 and its SIC code is 8071.